Interferon-y lb: Impact of new indications (idiopathic pulmonary fibrosis)

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 7, 2000, Pages 1423-1427

  Aggarwal, Ashutosh N ^a   Behera, Digamber ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Antifibrotic drugs; Collagen; Ftbrogenesis; Lung fibrosis

Indexed keywords

RECOMBINANT GAMMA INTERFERON;

HUMAN; LUNG FIBROSIS; PATHOLOGY; REVIEW;

HUMANS; INTERFERON-GAMMA, RECOMBINANT; PULMONARY FIBROSIS;

EID: 0034569824     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.7.1423     Document Type: Article

References (35)

1. AMERICAN THORACIC SOCIETY: Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am. J. Rcspir. Crit. Care. Med. (2000) 161:646-664. Well referenced review of current knowledge on clinical aspects of IFF.
2. TAYLOR ML, NOBLE PV, VHITE B, WISE R, LIU MC, BOCHNER BS: Extensive surface phenotyping of alveolar macrophages in interstitial lung disease. Clin. Immunol. (2000) 94:33-41.
3. LYNCH JP III, MCCUNE WJ: Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am.J. Rcspir. Crit. Care Med. (1997) 155:395-420.
4. BEHERA D, GUPTA D, J1NDAL SK: Response to steroid therapy in patients of idiopathic pulmonary fibrosis: a retrospective analysis. Indian J. Chest Dis. Allied Sei. (1998) 40:163-169.
5. MASON RJ, SCHWARZ MI, HUNN1NGHAKE GW, MUSSON RA: NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present and future. Am.J. Kespir. Crit. Care Med. (1999) 160:1771-1777. Concise summary of currently available and experimental treatment options in IFF.
6. RAGHU G, JOHNSON WC, LOCKHART D, MAGETO Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfcnidonc. Results of a prospective, open-label Phase H study. Am.J. Kespir. Crit. CareMed. (1999) 159:1061-1069.
7. COKER RK, LAURENT GJ: Pulmonary fibrosis: cytokines in the balance. Eur. Kespir. J. (1998) 11:1218-1221. Discussion of interactions between fibrogenic and antifibrotic cytokines in IFF.
8. PRIOR C, HASLAM CL: In vivo levels and in vitro production of interferon-gamma in fibrosing interstitial lung diseases. Clin. Exp. Immimol. (1992) 88:280-287.
9. LESUR OJ, MANCINI NM, HUMBERT JC, CHABOT F, POLU JM: Interleukin-6, interferon-gamma and phospholipid levels in the alveolar lining fluid of human lung. Profiles in coal worker's pneumoconiosis and idiopathic pulmonary fibrosis. Chest (1994) 106:407-413.
10. KUROKI S, OHTA A, SUEOKA N, KATOH O, YAMADA H, YAMAGUCHI M: Determination of various cytokines and Type III procollagen aminopeptide levels in bronchoalveolar lavage fluid of the patients with pulmonary fibrosis: inverse correlation between Type II procollagen aminopeptide and interferon-gamma in progressive patients. Br. J. Rheitmatol. (1995) 34:31-36.
11. WALLACE VA, RAMAGE EA, LAMB D, HOW1E SE: A Type 2 (Th2-like) pattern of Immune response predominates in the pulmonary interstitium of patients with cryptogénie fibrosing alyeolitis (CFA). Clin. Exp. Imnninol. (1995) 101:436-441. '
12. WALLACE WA, HOWIE SE: Immunoreactive interleukin 4 and interferon-gamma expression by Type II alveolar epithelial cells in interstitial lung disease. J. Pathol. (1999) 187:47580.
13. MAJUMDAR S, LI D, ANSARI T et al.: Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur. Rcspir.J. (1999) 14:251-257.
14. SEMPOWSKI GD, DERDAK S, PHIPPS RP: Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets./ Cell Physiol. (1996) 167:290-296.
15. HYDE DM, HENDERSON TS, GIRISN, TYLER NK, STOVALL MY: Effect of murine gamma Interferon on the cellular responses to bleomycin in mice. Exp. Liuig Res. (1988) 14:687-704.
16. OKADA T, SUGIE I, AISAKA K: Effects of gamma Interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lympbokine Cytokine Res. (1993) 12:87-91.
17. GURUJEYALAKSHMI G, GIRISN: Molecular mechanisms of antifibrotic effect of Interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and M gene expression. Exp. Lung Res. (1995) 21:791-808.
18. BIENKOWSKI RS, GOTKIN MG: Control of collagen deposition in mammalian lung. Proc. Soc. Exp. Btol. Mcd. (1995) 209:118-140. Discussion of positive and negative processes influencing collagen deposition in lung.
19. KEANE MP, BELPERIO JA, ARENBERG DA el al.-. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.J. Immtinol. (1999) 163:5686-5692.
20. Z1A S, HYDE DM, GIRI SN: Effects of an Interferon inducer bropirimine on bleomycin-induced lung fibrosis in hamster. Pharmaml. Toxicol. (1992) 71:11-18.
21. GIRI SN, HYDE DM: Ameliorating effect of an Interferon inducer polylnoslnic-polycytidilic acid on bleomycin-induced lung fibrosis in hamsters. Morphologic and biochemical evidence. Am.J. Pathol. (1988) 133:525-536.
22. CLARK JG, DEDON TF, VAYNER EA, CARTER VG: Effects of interferon-gamma on expression of cell surface receptors for collagen and deposition of newly synthesized collagen by cultured human lung fibroblasts. J. din. Invest. (1989) 83:1505-1511.
23. NARAYANAN AS, WITHEY J, SOUZA A, RAGHU G: Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. Chest (1992) 101:1326-1331.
24. TAMURA R, SATO ACHIDA K, SUGANUMA H: Fibroblasts as target and effector cells In Japanese patients with sarcoidosis. iiig(1998) 176:75-87.
25. ELIAS JA, FREUNDLICH B, KERN JA, ROSENBLOOM J: Cytokine networks in the regulation of inflammation and fibrosis in the lung. Of?/(1990) 97:1439-1435.
26. ADELMANN-GRILL BC, KEIN R, WACH F, KRIEG T: Inhibition of fibroblast chemotaxis by recombinant human Interferon gamma and Interferon alpha.J. CellPhysiol. (1987) 139:270-275.
27. INOUE Y, KING TEJ, TINKLE SS, DOCKSTADER K, NEWMAN LS: Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am.J. Pathol. (1996) 149:2037-2054.
28. KASAMA T, STRIETER RM, LUKACS NW, LINCOLN PM, BURDICK MD, KUNKEL SL: Interferon gamma modulates the expression of neutrophil-derived chemoklnes.y. Invest. Mcd. (1995) 43:58-67.
29. PHAM SH: The myofibroblast as an inflammatory cell in pulmonary fibrosis. Curr. Top. Pathol. (1999) 93:173-182.
30. GROSSMAN HJ, WHITE D, GROSSMAN VL, BHATHAL PS: Effect of Interferon gamma in intrahepatic hemodynamics of the cirrhotic rat liver. J. Gastroentcrol. Hcpatol. (1998) 13:1058-1060.
31. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J. Immiinol. (2000) 164:2110-2109.
32. ZIESCHE R, HOFBAUER E, WITTMANN K, PETKOV V, BLOCK LH: A preliminary study of long term treatment with Interferon gamma-lb and low-dose prednisolone in patients with idiopathic pulmonary fibrös is. N. Engl. J. Med. (1999) 341:1264-1269. The only randomised clinical trial on treatment of IFF using IFN-y.
33. JAFFE HA, BUHL R, MASTRANGELIA et al.: Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant Interferon gamma to the human lung. J. Clin. Invest. (1991) 88:297-302.
34. VIAL T, DESCOTESJ: Clinical toxicityof Üie interferons. DnigSaf. (1994) 10:115-150.
35. CONDOS R, ROM VN, SCHULGER NV: Treatment of multidrug-resistant pulmonary tuberculosis with intcrfcron-gamma via aerosol, lancet (1997) 349:1513-1515.